TOP TEN perturbations for 1553078_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553078_at
Selected probe(set): 1553078_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553078_at (1553078_at) across 6537 perturbations tested by GENEVESTIGATOR:

actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%) / actinic keratosis study 4 (lesion; baseline)

Relative Expression (log2-ratio):-1.5721369
Number of Samples:5 / 6
Experimental actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%)
Punch biopsies of skin lesions obtained from actinic keratosis patients after 2 days treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the second topical application with ingenol mebutate from cca 25 cm2 treated area. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had 2-5 clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:
Control actinic keratosis study 4 (lesion; baseline)
Punch biopsies of skin lesions obtained from actinic keratosis (AK) patients before treatment (baseline). The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm.

actinic keratosis study 4 (lesion; ingenol mebutate; 1d; 0.05%) / actinic keratosis study 4 (lesion; baseline)

Relative Expression (log2-ratio):-1.341486
Number of Samples:6 / 6
Experimental actinic keratosis study 4 (lesion; ingenol mebutate; 1d; 0.05%)
Punch biopsies of skin lesions obtained from actinic keratosis patients after 1 day treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the first topical application with ingenol mebutate from cca 25 cm2 treated area. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had 2-5 clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:
Control actinic keratosis study 4 (lesion; baseline)
Punch biopsies of skin lesions obtained from actinic keratosis (AK) patients before treatment (baseline). The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm.

actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%) / ingenol mebutate study 1 (uninvolved skin; 2d; 0.05%)

Relative Expression (log2-ratio):-1.0776243
Number of Samples:5 / 6
Experimental actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%)
Punch biopsies of skin lesions obtained from actinic keratosis patients after 2 days treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the second topical application with ingenol mebutate from cca 25 cm2 treated area. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had 2-5 clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:
Control ingenol mebutate study 1 (uninvolved skin; 2d; 0.05%)
Punch biopsies of uninvolved skin obtained from actinic keratosis patients after 2 days treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the second topical application with ingenol mebutate from cca 25-cm2 area of uninvolved, normal-appearing, aged but non-sun-exposed skin on the inner aspect of the upper arm. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):-0.9967556
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

ingenol mebutate study 1 (uninvolved skin; 2d; 0.05%) / uninvolved skin sample (baseline)

Relative Expression (log2-ratio):-0.9344187
Number of Samples:6 / 5
Experimental ingenol mebutate study 1 (uninvolved skin; 2d; 0.05%)
Punch biopsies of uninvolved skin obtained from actinic keratosis patients after 2 days treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the second topical application with ingenol mebutate from cca 25-cm2 area of uninvolved, normal-appearing, aged but non-sun-exposed skin on the inner aspect of the upper arm. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:
Control uninvolved skin sample (baseline)
Punch biopsies of uninvolved skin obtained from actinic keratosis (AK) patients before treatment (baseline). Samples were taken from cca 25 cm2 area of uninvolved, normal-appearing, aged but non-sun-exposed skin on the inner aspect of the upper arm. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm.

engineered skin substitute study 2 (intermediate) / engineered skin substitute study 1 (intermediate)

Relative Expression (log2-ratio):0.92715263
Number of Samples:6 / 3
Experimental engineered skin substitute study 2 (intermediate)
Human skin substitutes tissue samples collected after 14 and 28 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (intermediate)
Human skin substitutes tissue samples collected after 7 days in culture.

glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-0.92278576
Number of Samples:2 / 4
Experimental glioma study 17 ( small cell glioblastoma; unsorted)
Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

rhegmatogenous retinal detachment study 1 / normal retina tissue

Relative Expression (log2-ratio):-0.9060879
Number of Samples:19 / 17
Experimental rhegmatogenous retinal detachment study 1
Retina tissue samples from patients with retinal detachment obtained by vitrectomy.
Control normal retina tissue
Postmortem retina tissue samples from healthy patients without any diseases of the eye.

DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; dead) / DLBCL study 4 (unclassified DLBCL; baseline; CHOP; dead)

Relative Expression (log2-ratio):-0.82764244
Number of Samples:5 / 17
Experimental DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; dead)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP) and during follow up period they died from unknown reasons.
Control DLBCL study 4 (unclassified DLBCL; baseline; CHOP; dead)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and during follow up period they died from unknown reasons.

glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-0.7631459
Number of Samples:2 / 4
Experimental glioma study 17 (glioblastoma; unsorted)
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.